Immune checkpoint inhibitors (ICIs) have transformed treatment for many types of cancer. In some patients, however, ICIs are associated with immune-related complications that can affect the kidneys. These complications sometimes require care teams to pause or discontinue lifesaving treatment. A study led by Sandra Herrmann, M.D., an onconephrologist and researcher at Mayo Clinic, helps clarify how immune-related kidney inflammation develops and provides preclinical evidence supporting a targeted approach that could improve how these side effects are managed—and could potentially be prevented.
This article was originally published on MedicalXpress.com
